Research Article
Policosanol Attenuates Statin-Induced Increases in Serum Proprotein Convertase Subtilisin/Kexin Type 9 When Combined with Atorvastatin
Table 1
(a) Baseline clinical characteristics of Protocol I. (b) Baseline clinical characteristics of Protocol II.
| (a) |
| | Variable | Atorvastatin | Policosanol
+ atorvastatin | value |
| | Number of patients | 12 | 14 | | | Demographics | | | | | Age (years; mean ± SD) | 55.31 ± 6.72 | 54.73 ± 7.35 | >0.05 | | Men [ (%)] | 6 (50.0) | 11 (78.6) | >0.05 | | Body mass index (kg/m2; mean ± SD) | 25.73 ± 2.93 | 26.26 ± 3.40 | >0.05 | | Clinical profile [ (%)] | | | | | Hypertension | 7 (58.3) | 8 (61.5) | >0.05 | | Diabetes | 4 (33.3) | 6 (46.2) | >0.05 | | Family history of coronary heart disease | 1 (8.3) | 2 (15.4) | >0.05 | | Smoker | 6 (50.0) | 6 (46.2) | >0.05 | | Laboratory values (mean ± SD) | | | | | White blood cell count (×109/L; mean ± SD) | 7.54 ± 1.66 | 6.15 ± 1.61 | 0.04 | | Neutrophils (×109/L; mean ± SD) | 4.46 ± 1.05 | 3.30 ± 1.06 | 0.01 | Erythrocyte sedimentation rate
(mm/h; mean ± SD) | 12.78 ± 13.09 | 9.86 ± 10.26 | >0.05 | high-sensitivity C-reactive protein
[mg/L; median (P25, P75)] | 2.86
(1.18, 10.99) | 1.27
(0.90, 1.82) | >0.05 | | Alanine transaminase (U/L; mean ± SD) | 28.00 ± 12.10 | 28.71 ± 15.09 | >0.05 | | Aspartate aminotransferase (U/L; mean ± SD) | 19.58 ± 7.86 | 21.29 ± 10.38 | >0.05 | | Creatinine (mol/L; mean ± SD) | 71.74 ± 14.64 | 75.20 ± 8.80 | >0.05 | | Blood urea nitrogen (mmol/L; mean ± SD) | 5.68 ± 1.36 | 5.91 ± 1.47 | >0.05 |
|
|
| (b) |
| | Variable | Control | Policosanol 20 mg | value |
| | Number of patients | 8 | 7 | | | Demographics | | | | | Age (years; mean ± SD) | 45.0 ± 9.9 | 34.0 ± 3.4 | 0.017 | | Men [ (%)] | 4 (50.0) | 4 (57.1) | >0.05 | | Body mass index (kg/m2; mean ± SD) | 23.98 ± 1.81 | 21.76 ± 1.70 | >0.05 | | Clinical profile [ (%)] | | | | | Hypertension | 1 (12.5) | 0 (0) | >0.05 | | Diabetes | 0 (0) | 0 (0) | >0.05 | | Family history of coronary heart disease | 0 (0) | 1 (14.3) | >0.05 | | Smoker | 2 (25.0) | 1 (14.3) | >0.05 | | Laboratory values | | | | high-sensitivity C-reactive protein
[mg/L; median (P25, P75)] | 1.11
(0.30, 2.66) | 0.69
(0.30, 1.43) | >0.05 | | Fasting blood glucose (mmol/L; mean ± SD) | 5.09 ± 0.35 | 4.84 ± 0.43 | >0.05 | | Alanine transaminase (U/L; mean ± SD) | 26.57 ± 17.82 | 22.14 ± 14.72 | >0.05 | | Aspartate aminotransferase (U/L; mean ± SD) | 19.00 ± 6.19 | 18.57 ± 4.54 | >0.05 | | Creatinine (mol/L; mean ± SD) | 70.06 ± 12.96 | 71.07 ± 9.91 | >0.05 | | Blood urea nitrogen (mmol/L; mean ± SD) | 5.49 ± 1.39 | 5.25 ± 1.60 | >0.05 | | Uric acid (mol/L; mean ± SD) | 322.6 ± 76.9 | 344.1 ± 114.8 | >0.05 |
|
|
